Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes.
Mucinous carcinoma
molecular subtype
prognosis
Journal
European journal of breast health
ISSN: 2587-0831
Titre abrégé: Eur J Breast Health
Pays: Turkey
ID NLM: 101709357
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
27
08
2022
accepted:
09
09
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
A few studies suggest that mucinous breast carcinoma (MBC) is a rare breast carcinoma with good prognostic features. Therefore, the aim of this study was to evaluate biological features and clinicopathological characteristics of pure mucinous breast carcinoma (PMBC) to determine clinical outcome in PMBC. The data of 87 patients diagnosed with PMBC between November 2004 and February 2022 were retrospectively analyzed in terms of clinicopathological and demographic characteristics, management, and outcome. The majority of the patients in this study were female, with a median (range) age of 63 (28-90) years. Out of 87 patients, 60 had breast conserving surgery, 27 had a mastectomy, 58 had sentinel lymph node biopsy (SLNB), and 24 had axillary dissection due to a positive SLNB or clinical axilla. Due to age and comorbidities, five patients were not suitable for axillary surgery. The median largest tumor diameter was 23 (5-100) mm. Only 23 patients (26.4%) received adjuvant chemotherapy, whereas almost all patients received hormone therapy. The median duration of follow-up was 53 (6-207) months. There was no local or systemic recurrence in any of the patients. Only 10 patients (11.5%) died from non-cancer causes during the follow-up and treatment period. In this study, tumor diameter was significantly higher in grade II/III tumors ( In this study, the majority of patients were in the luminal subgroups with excellent prognosis and low incidences of lymph node metastasis. As a result, PMBC has favorable tumor biology. We believe that minimal axillary surgery would be the most appropriate approach during patient treatment, due to the low rate of lymph node involvement and favorable prognosis in PMBC patients.
Identifiants
pubmed: 36248750
doi: 10.4274/ejbh.galenos.2022.2022-8-1
pii: 53095
pmc: PMC9521282
doi:
Types de publication
Journal Article
Langues
eng
Pagination
353-359Informations de copyright
©Copyright 2022 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
AJR Am J Roentgenol. 2002 Jul;179(1):179-83
pubmed: 12076930
BMC Cancer. 2021 May 11;21(1):536
pubmed: 33975551
AJR Am J Roentgenol. 1994 Oct;163(4):821-4
pubmed: 8092016
Front Oncol. 2021 Mar 01;10:558760
pubmed: 33732635
J Clin Oncol. 1999 May;17(5):1442-8
pubmed: 10334529
Hum Pathol. 1989 Aug;20(8):758-64
pubmed: 2545592
Can Assoc Radiol J. 1995 Aug;46(4):296-301
pubmed: 7543806
Eur J Radiol. 2000 Jul;35(1):39-43
pubmed: 10930764
J Lab Physicians. 2020 Mar;12(1):68-75
pubmed: 32792796
Breast Care (Basel). 2013 Jun;8(3):221-9
pubmed: 24415975
Breast Cancer Res Treat. 2002 Dec;76(3):255-60
pubmed: 12462386
Clin Radiol. 2006 May;61(5):423-30
pubmed: 16679116
Am J Surg. 2004 Apr;187(4):528-32
pubmed: 15041505
Eur J Radiol. 2006 Dec;60(3):405-13
pubmed: 16963218
Hum Pathol. 1986 Jan;17(1):34-8
pubmed: 3002950
AJR Am J Roentgenol. 2016 Feb;206(2):238-46
pubmed: 26797349
Am J Surg. 2007 Oct;194(4):527-31
pubmed: 17826073
Am J Clin Pathol. 1987 Feb;87(2):155-60
pubmed: 3028120
AJR Am J Roentgenol. 1995 Aug;165(2):285-9
pubmed: 7618541
Breast Cancer. 2000 Jan;7(1):65-70
pubmed: 11029773
Breast Cancer Res Treat. 2008 Oct;111(3):541-7
pubmed: 18026874
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
J Natl Cancer Inst. 2019 Jul 1;111(7):737-741
pubmed: 30649385